Evenly Poised on Regeneron - Analyst Blog - On Jun 20, 2013, we - TopicsExpress



          

Evenly Poised on Regeneron - Analyst Blog - On Jun 20, 2013, we retained our Neutral recommendation on biopharmaceutical company Regeneron Pharmaceuticals Inc. ( REGN ). Our investment thesis is supported by a Zacks Rank #3 (Hold). Why the Reiteration? Regeneron reported higher-than-expected earnings in the first quarter of 2013, on the back of strong sales of its eye-drug Eylea. The drug has performed well since its US launch in late 2011 for treating patients suffer... ht.ly/2xS1mC
Posted on: Tue, 25 Jun 2013 18:39:27 +0000

Trending Topics



Recently Viewed Topics




© 2015